NZX-listed cancer diagnostics company Pacific Edge will need to “batten down the hatches” following a long-awaited decision on whether its Cxbladder product will be funded by the US Medicare scheme.
It’s an issue that has dominated the company’s business since June 2023.
The company has gone
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
